Office: Cambridge, MA
Nicholas Galakatos, PhD
Nicholas Galakatos, PhD, has been Managing Director of Clarus Ventures since the firm's inception in 2005. Prior to Clarus, Dr. Galakatos was a General Partner at MPM Capital, a healthcare venture capital firm. He has over 27 years of industry and investment experience in the healthcare sector. From 1997 to 2000, Dr. Galakatos was Vice President of New Business at Millennium Pharmaceuticals (presently Takeda) and a member of the Management Team. He is founder of Millennium Predictive Medicine and TransForm Pharmaceuticals, where he was the Chairman and founding CEO. Prior to Millennium he was at Venrock Associates focusing on early stage biotechnology investments. Prior to Venrock he was Head of Molecular Biology Research at Novartis (formerly Ciba).
Dr. Galakatos earned his PhD in Organic Chemistry from MIT and performed his post-doctoral studies at Harvard Medical School.
In addition he is a member of the Director’s Council of the Koch Institute at MIT, and a member of the Genetics Advisory Council at Harvard Medical School.
He was the chairman of Transform (acquired by J&J), Hypnion (acquired by Eli Lilly) and the Lead Director of Affymax (NASDAQ: AFFY). Previous directorships also include Aveo (NASDAQ:AVEO), Caliper (NASDAQ:CALP), Critical Therapeutics (NASDAQ:CRTX), Link Medicine (acquired by AstraZeneca), Millennium Biotherapeutics (acquired by Millennium), Millennium Predictive Medicine (acquired by Millennium), Syrrx (acquired by Takeda) and Taligen (acquired by Alexion.)